- CBD
Biotech seizing immense opportunities in untapped CBD Chinese market
- CIIX
operates both online, physical CBD stores in addition to developing first
Chinese, CBD-based social media app
- CIIX’s
hemp-based products fully legal in China with plans for further
development, Nasdaq IPO this year
ChineseInvestors.com Inc. (OTCQB: CIIX), a leading
U.S.-based financial consultancy for Chinese-speaking investors, is positioning
its subsidiary, CBD Biotech Inc., as a leader in the Chinese-based CBD market
through increased development of legal hemp-based products.
Clinically shown to help with anxiety and stress-related
disorders (http://ibn.fm/dbNam),
CBD-based products may be helpful for dealing with the coronavirus outbreak,
CIIX CEO Warren Wang stated during a recent interview (http://ibn.fm/myK5y). While
clarifying that medical help is essential, Wang shared his opinion that CBD
products “can help your immune system.” Wang also noted that CBD Biotech Inc.
will be “the first one in the public market field inside China selling CBD.”
In partnership with a well-known CBD brand, CIIX currently
markets to the massive Chinese-speaking market worldwide through its website
ChineseCBDOil.com – one of the world’s first online stores in the Chinese
language that provides industrial-hemp-derived, CBD soft gels, capsules and
concentrates. In order to support the company’s online efforts, CIIX has
developed a Yelp-style mobile app to be used as a platform for Chinese
consumers to review and discuss various cannabis products, making it the first
marijuana-based social media mobile application for Chinese-speaking customers
in the world. In addition to operating online, CIIX also serves the Chinese
population of San Gabriel, California, through its retail store.
With few competitors and plenty of room for market
dominance, CIIX plans to seize opportunities in the fully legal, hemp-based CBD
nutritional and cosmetic product markets in China. While cannabis is still
illegal in the country, prohibitory laws do not apply to hemp-based CBD
cosmetics. Unaffected by changing regulations, CIIX is able to operate in a
stable environment with the freedom to focus investment on the research and
development of new CBD products. The company has established a three-year
development plan for CBD Biotech in mainland China and has hopes for a Nasdaq
IPO in 2020.
With a global Chinese-speaking base that continues to grow,
CIIX disseminates investment information through its proprietary financial news
media and content platform. The company assists its subscriber base in making
informed investment choices through its exclusive service, called the
ChineseInvestors Method. This investment strategy integrates personalized
advice with web-based tools, empowering Chinese investors to make optimal
investment decisions based on their needs and risk profile. All services by the
company are offered in both traditional and simplified Chinese-language
character sets (http://ibn.fm/NiIwr).
Besides offering its audience of investors real-time market
commentary, analysis and educational-related services, the company also
provides consulting services to smaller private companies that wish to go
public, in addition to advertising, social media, and public relations
consulting services.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
